| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3989284 | Journal of Thoracic Oncology | 2016 | 6 Pages |
Abstract
A growing number of NSCLC trials are requiring tumor tissue for treatment eligibility, which appears to be a significant barrier to trial enrollment. Potential solutions include use of available diagnostic samples (e.g., cytology samples), development of peripheral blood assays for molecular markers, faster central laboratory testing turnaround time, and more resources for rapid biopsy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Charles MD, Mike BSc, Frances A. MD, Nazanin RN, Magdalena RN, Tuhina RN, Nicole RN, Andrea RN, Dianne RN, Ronald MD, Geoffrey MD, MSc, Natasha B. MD, MMSc,